You are an Investor
De-risking life science investments with QUASY™.
For business angels in the life science sector and pre-seed / seed VCs.
De-risking life science investments means systematically reducing the uncertainty around your stake. The high capital requirements, the regulatory complexity, and long development timelines make this particularly relevant in our field.
The risks you actually carry
- Scientific and technological risk: Will the technology work as expected? In life sciences, that means proving efficacy and safety of a drug or device.
- Regulatory risk: Start-ups operate in a complex regulatory landscape. Approval by bodies like the FDA or EMA is essential but never guaranteed.
- Market risk: Even a scientifically sound, approved product is not automatically a commercial success.
- Financial risk: Life science ventures tie up substantial capital over long periods before any return materialises.
- Start-up-specific risk: Teams break apart, focus is lost, or the company evolves less linearly than planned.
Strategies for de-risking
- Robust due diligence: Systematically scrutinise the technology, business plan, market potential, and regulatory strategy.
- Milestone-based funding: Tie tranches to achieved phases (clinical trial phases, regulatory approvals) to manage exposure.
- Strategic alliances: Partnerships with established companies bring experience, resources, and credibility.
- Regulatory expertise: External specialists reduce the complexity of approval processes.
- Market analysis and validation: Solid market research validates demand and the business model.
- Quality management systems like QUASY: A robust QMS reduces the risk of costly errors and regulatory setbacks.
The impact of de-risking
- Stronger investability: De-risked ventures are more attractive to follow-on investors and industry partners because the risk-reward profile is more balanced.
- Higher chance of success: Systematically addressing risks improves the odds of both scientific and commercial success.
- Credibility: A well-designed de-risking strategy strengthens the start-up’s position with partners, follow-on investors, and authorities.
De-risking is not about eliminating all risks – impossible in this field. It is about understanding, managing, and mitigating risks to enable informed decisions and improve the likelihood of success.
What QUASY means for investors
Risk mitigation: Implementing QUASY from the start reduces regulatory and financial risk, absorbs personnel turnover through standardised processes, enables credible industry partnerships, secures data integrity, and lifts enterprise value through trust and compliance.
Operational efficiency: A live QMS / eQMS lifts operational efficiency. Run inside one of our managed environments, you reach this goal without constant escalations.
Getting started with QUASY
We can hedge your risk by deploying a QMS within days or weeks instead of months – the moment the parties decide to get serious. The start-up’s business continuity is barely affected; the team can focus on developing the product, now on a robust basis.
In case of joint involvement, we may offer discounted pricing.
Contact: sales@austrianpharmaservices.com
Are you a traditional financial investor? Feel free to reach out to discuss options.
A deal in preparation?
We assess anonymously where the actual compliance risk sits – and tell you straight whether QUASY is the right lever.